Dharmishta Parmar

Dharmishta Parmar

Auto-generated profile, based on publicly available information

Dharmishta Parmar

Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2013 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
SDStephen W. Duffy
Stephen W. Duffy
DPDharmishta Parmar
Dharmishta Parmar
Breast Cancer Research is the leading journal in the breast cancer field. The journal publishes research and reviews of exceptional interest covering all areas of biology and medicine relevant to breast cancer, with a special emphasis on the genetic, biochemical and cellular basis of breast cancer. As an international journal with open access to all publications the journal serves as essential reading to all researchers, clinicians, students and related healthcare professionals working in the field of breast cancer.

1 October 2020 in Health Technology Assessment
Verified
Journal Article
Closed access
SDStephen W. Duffy
Stephen W. Duffy
DVDaniel Vulkan
Daniel Vulkan
HCHoward Cuckle
Howard Cuckle
DPDharmishta Parmar
Dharmishta Parmar
SSShama Sheikh
Shama Sheikh
SMSue Moss
Sue Moss
Background: There remains disagreement on the long-term effect of mammographic screening in women aged 40–49 years. Objectives: The long-term follow-up of a randomised controlled trial that offered annual mammography to women aged 40–49 years. The estimation of the effect of these mammograms on breast cancer and other-cause mortality, and the effect on incidence, with implications for overdiagnosis. Design: An individually randomised controlled trial comparing offering annual mammography with offering usual care in those aged 40–48 years, and thus evaluating the effect of annual screening entirely taking place before the age of 50 years. There was follow-up for an average of 23 years for breast cancer incidence, breast cancer death and death from other causes. We analysed the mortality and incidence data by Poisson regression and estimated overdiagnosis formally using Markov process models. Setting: Twenty-three screening units in England, Wales and Scotland within the NHS Breast Screening Programme. Participants: Women aged 39–41 years were recruited between 1990 and 1997. After exclusions, a total of 53,883 women were randomised to undergo screening (the intervention group) and 106,953 women were randomised to have usual care (the control group). Interventions: The intervention group was invited to an annual breast screen with film mammography, two view at first screen and single view thereafter, up to and including the calendar year of their 48th birthday. The control group received no intervention. Both groups were invited to the National Programme from the age of 50 years, when screening is offered to all women in the UK. Main outcome measures: The main outcome measures were mortality from breast cancers diagnosed during the intervention phase of the trial (i.e. before the first National Programme screen at 50 years), mortality from all breast cancers diagnosed after randomisation, all-cause mortality, mortality from causes other than breast cancer, and the incidence of breast cancer. Results: There was a statistically significant 25% reduction in mortality from breast cancers diagnosed during the intervention phase at 10 years’ follow-up (relative rate 0.75, 95% confidence interval 0.58 to 0.97; p = 0.03). No reduction was observed thereafter (relative rate 0.98, 95% confidence interval 0.79 to 1.22). Overall, there was a statistically non-significant 12% reduction (relative rate 0.88, 95% confidence interval 0.74 to 1.03; p = 0.1). The absolute benefit remained approximately constant over time, at one death prevented per 1000 women screened. There was no effect of intervention on other-cause mortality (relative rate 1.02, 95% confidence interval 0.97 to 1.07; p = 0.4). The intervention group had a higher incidence of breast cancer than the control group during the intervention phase of the trial, but incidence equalised immediately on the first National Programme screen at the age of 50–52 years. Limitations: There was 31% average non-compliance with screening and three centres had to cease screening for resource and capacity reasons. Conclusions: Annual mammographic screening at the age of 40–49 years resulted in a relative reduction in mortality, which was attenuated after 10 years. It is likely that digital mammography with two views at all screens, as practised now, could improve this further. There was no evidence of overdiagnosis in addition to that which already results from the National Programme carried out at later ages. Future work: There is a need for research on the effects of modern mammographic protocols and additional imaging in this age group. Trial registration: Current Controlled Trials ISRCTN24647151. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 55. See the NIHR Journals Library website for further project information. Other funding in the past has been received from the Medical Research Council, Cancer Research UK, the Department of Health and Social Care, the US National Cancer Institute and the American Cancer Society.

18 July 2022 in Cancer Medicine
Verified
Journal Article
Open access
OBOleg Blyuss
Oleg Blyuss
ADAmanda Dibden
Amanda Dibden
NMNathalie J. Massat
Nathalie J. Massat
DPDharmishta Parmar
Dharmishta Parmar
JCJack Cuzick
Jack Cuzick
PSPeter Sasieni
Peter Sasieni
Background There is uncertainty about overdiagnosis in mammography screening. Methods We aimed to estimate the effect of screening on breast cancer incidence and overdiagnosis in the NHS Breast Screening Programme in England. The study included 57,493 cases and 105,653 controls, with cases defined as women diagnosed at ages 47-89 with primary breast cancer, invasive or ductal carcinoma in situ, in 2010 or 2011. Where possible, two controls were selected per case, matched on date of birth and screening area. Conditional logistic regression was used to estimate the effect of screening on breast cancer risk, with adjustment for potential self-selection bias. Results were combined with national incidence data to estimate absolute rates of overdiagnosis. Overdiagnosis was calculated as the cumulative excess of cancers diagnosed in the age group 50-77 in a woman attending three-yearly screening between ages 50 and 70 compared with a woman attending no screens. Results The estimated number of cases overdiagnosed in women attending all screens in the programme was 679.3 per 100,000 without adjustment for self-selection bias and 261.2 per 100,000 with adjustment. These corresponded to an estimated 9.5% of screen-detected cancers overdiagnosed without adjustment and 3.7% with adjustment for self-selection. Conclusions The NHS Breast Screening Programme in England confers at worst modest levels of overdiagnosis.

13 December 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NMNathalie J Massat
Nathalie J Massat
PSPeter Sasieni
Peter Sasieni
DPDharmishta Parmar
Dharmishta Parmar
SDStephen W. Duffy
Stephen W. Duffy
In England, a national breast screening programme (NHSBSP) has been in place since 1988, and assessment of its impact on breast cancer incidence and mortality is essential to ensure that the programme is indeed doing more good than harm. This article describes large observation studies designed to estimate the effects of the current programme in terms of the benefits on breast cancer incidence and mortality and detrimental effect in terms of overdiagnosis. The case-control design of the cervical screening programme evaluation was highly effective in informing policy on screening intervals and age ranges. We propose innovative selection of cases and controls and gathering of additional variables to address new outcomes of interest and develop new methodologies to control for potential sources of bias.

16 May 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Alejandra CastanonAlejandra Castanon
Alejandra Castanon
DPDharmishta Parmar
Dharmishta Parmar
NMNathalie J Massat
Nathalie J Massat
PSPeter Sasieni
Peter Sasieni
SDStephen W. Duffy
Stephen W. Duffy
Background: The English national bowel cancer screening program offering a guaiac fecal occult blood test began in July 2006. In randomized controlled trials of guaiac fecal occult blood test screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the national bowel cancer screening program on stage-specific CRC incidence as a likely precursor of a mortality effect. Methods: In this population-based case-control study, cases were individuals diagnosed with CRC aged 60-79 years between January 1, 2012, and December 31, 2013. Two controls per case were matched on geographic region, gender, date of birth, and year of first screening invitation. Screening histories were extracted from the screening database. Conditional logistic regression with correction for self-selection bias was used to estimate odds ratios (odds ratios corrected for self-selection bias [cOR]) and 95% confidence intervals (CIs) by Duke stage, sex, and age. Results: 14 636 individuals with CRC and 29 036 without were eligible for analysis. The odds of CRC (any stage) were increased within 30 days of a screening test and decreased thereafter. No reduction in CRC (any stage) among screened individuals compared with those not screened was observed (cOR = 1.00, 95% CI = 0.89 to 1.15). However, screened individuals had lower odds of Duke stage D CRC (cOR = 0.68, 95% CI = 0.50 to 0.93). We estimate 435 fewer Duke D CRC by age 80 years in 100 000 people screened biennially between ages 60 and 74 years compared with an unscreened cohort. Conclusion: The impact of colorectal screening on advanced CRC incidence suggests that the program will meet its aim of reducing mortality.

26 June 2026 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADAmanda Dibden
Amanda Dibden
DPDharmishta Parmar
Dharmishta Parmar
RGRhian Gabe
Rhian Gabe
RSRobert A. Smith
Robert A. Smith
SMSue M. Moss
Sue M. Moss
SDStephen W. Duffy
Stephen W. Duffy
Background: Population-based mammographic screening programmes have been operating for over 30 years and whilst many studies have assessed the short- to medium-term effectiveness of screening, few have assessed their long-term effectiveness. The aim of this study was to assess the long-term effectiveness of the NHS Breast Screening Programme in England and Wales. Methods: 2,509,384 women aged 49–64 years and uninvited to screening upon study entry were studied, with screening status changing on invitation and attendance. Women were followed for breast cancer diagnosis and death for a maximum of 33 years. Poisson regression was used to assess the effect of screening on breast cancer incidence and mortality compared to an uninvited comparison group, and overdiagnosis. Results: After adjustment for confounders, invitation to screening was associated with a 28% reduction in breast cancer mortality (RR: 0.72; 95% CI: 0.71–0.74) and attendance at screening was associated with a 33% reduction (RR: 0.67; 95% CI: 0.65–0.69). There was a 4% excess of breast cancer diagnoses associated with being screened (RR: 1.04; 95% CI: 1.02–1.07) with at least 5 years follow-up post-screening. Conclusion: These findings indicate that screening continues to be effective in reducing breast cancer mortality many years after cessation of screening and that the level of overdiagnosis associated with long-term follow-up is low.